Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 31.38M | 31.38M | 63.04M | 976.18M | 642.49M | 314.18M |
Gross Profit | 30.56M | 31.38M | 30.61M | 338.49M | 198.80M | 236.11M |
EBITDA | -2.09B | -1.68B | -1.93B | -1.14B | -1.60B | -2.08B |
Net Income | -2.13B | -1.68B | -1.94B | -1.15B | -1.62B | -2.10B |
Balance Sheet | ||||||
Total Assets | 2.31B | 3.20B | 2.04B | 2.65B | 4.29B | 2.80B |
Cash, Cash Equivalents and Short-Term Investments | 1.74B | 2.41B | 1.53B | 1.71B | 3.45B | 2.07B |
Total Debt | 288.78M | 324.64M | 315.17M | 393.66M | 503.47M | 525.08M |
Total Liabilities | 373.88M | 446.65M | 566.50M | 491.69M | 697.88M | 793.09M |
Stockholders Equity | 1.94B | 2.75B | 1.47B | 2.16B | 3.59B | 2.00B |
Cash Flow | ||||||
Free Cash Flow | 0.00 | -2.02B | -1.34B | -1.72B | -1.74B | -1.47B |
Operating Cash Flow | 0.00 | -2.02B | -1.34B | -1.72B | -1.74B | -1.47B |
Investing Cash Flow | 0.00 | -4.71M | -5.39M | 20.12M | -942.00K | -37.58M |
Financing Cash Flow | 0.00 | 2.88B | 1.14B | -113.83M | 3.09B | 242.26M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
66 Neutral | ¥11.99B | 284.55 | 0.83% | -13.57% | -106.11% | ||
51 Neutral | $7.92B | -0.43 | -41.67% | 2.21% | 22.29% | -1.85% | |
50 Neutral | ¥13.41B | ― | ― | 268.05% | 83.57% | ||
48 Neutral | ¥9.39B | ― | ― | 30.92% | 26.00% | ||
47 Neutral | ¥13.75B | ― | ― | 40.66% | 24.86% | ||
47 Neutral | ¥19.32B | ― | ― | ― | 8.47% | ||
44 Neutral | ¥16.90B | ― | ― | -9.04% | 2.12% |
Oncolys BioPharma Inc. reported its non-consolidated financial results for the first half of 2025, revealing a decline in net sales and increased losses compared to the previous year. The company’s net sales dropped to 28 million yen, with operating and ordinary profits showing significant negative figures. Despite the challenging financial performance, the company maintains a strong equity ratio, although its total assets and net assets have decreased. The financial results indicate ongoing challenges in the company’s operations, which may impact its market positioning and stakeholder confidence.